Aldeyra Therapeutics' NDA for Reproxalap Accepted by FDA for Dry Eye Disease Treatment

Aldeyra Therapeutics Advances in Dry Eye Disease Treatment with FDA Review Acceptance

Aldeyra Therapeutics, Inc. makes significant strides in the ophthalmology sector as the U.S. Food and Drug Administration (FDA) accepts the resubmitted New Drug Application (NDA) for reproxalap, a groundbreaking investigational treatment for dry eye disease. The FDA has set the Prescription Drug User Fee Act (PDUFA) date for April 2, 2025, marking a pivotal moment for Aldeyra in bringing this first-in-class drug to market. Reproxalap functions as a small-molecule modulator of reactive aldehyde species (RASP), which are implicated in various inflammatory diseases, including dry eye disease and allergic conjunctivitis. The acceptance of the NDA signals the FDA's acknowledgment of the drug's potential benefits in addressing a condition that affects millions of individuals globally.

In conjunction with the NDA review, Aldeyra expands its partnership with AbbVie Inc. through an exclusive option agreement that allows AbbVie to co-develop, manufacture, and commercialize reproxalap in the U.S. If AbbVie chooses to exercise this option, Aldeyra stands to gain a $100 million upfront fee, along with potential milestone payments that could total up to $300 million, including a significant $100 million payment contingent upon FDA approval. This collaboration underscores the confidence both companies have in reproxalap's market potential and the strategic role of partnerships in advancing therapeutic innovations in the pharmaceutical landscape.

As Aldeyra prepares for the next stages in the development and commercialization of reproxalap, it initiates pre-commercial activities funded by both AbbVie and itself, with financial contributions split 60% from AbbVie and 40% from Aldeyra upon the exercise of the option. AbbVie has also begun its own pre-commercial planning, indicating a proactive approach to the potential launch of reproxalap. The amended agreement stipulates that the option will expire 10 business days post-FDA approval, should it be granted. With over 2,500 patients studied and no major safety concerns raised—aside from mild instillation site irritation—reproxalap demonstrates promise in enhancing treatment options for patients suffering from dry eye disease and allergic conjunctivitis.

In summary, Aldeyra Therapeutics is poised to make a significant impact in the ophthalmology field with the FDA's acceptance of its NDA for reproxalap. The expanded collaboration with AbbVie not only provides substantial financial backing but also emphasizes the joint commitment to addressing the unmet needs of patients with dry eye disease. As the April 2025 PDUFA date approaches, both companies are set to advance their preparations for what could be a transformative addition to the treatment landscape.